Brought to you by 
Sucampo, Takeda enter constipation drug deal
31 Aug 2021
Executive Summary
Sucampo (R&D oriented biotech focusing on under-treated niche diseases) and Takeda will collaborate on the development of lubiprostone (SPI-0211), a late-stage compound in Sucampo's pipeline for indications in chronic constipation (completed Phase III) and constipation-predominant irritable bowel syndrome (completed Phase II).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sucampo, Takeda enter constipation drug deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice